Sandra Hay Bryson A Dedication and Memorial Page

image1.jpeg

Sandra Hay Bryson

Our beloved mother, wife, sister, aunt, and friend was tragically and suddenly taken from us on the
19th of December 2007 at a young age of 50 after a routine operation and then acquiring a C.diff. infection,  leading to her death 4 days later.

I am Lesley, daughter of Sandra Hay Bryson, and I have decided to join a team and push myself physically, mentally, and emotionally by stepping completely outside of my comfort zone and participating in ‘Tough Mudder’  in
June 2018 . I will be running in my Mum’s memory and to help ‘Raise C.diff. Awareness.’

 

 

 

 

 

Your  show of support with a donation will be greatly appreciated to help promote C.diff. Awareness’ worldwide with the C Diff Foundation, a 501(c) (3)  non-profit global organization, established in 2012, and comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for
C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide.

C Diff Foundation and C diff Survivors Alliance Network Winter 2017 Bulletin

 

Greetings from the main office of the C Diff Foundation and the C diff Survivors Alliance Network located in New Port Richey, Florida.  As we close 2017 we mark the 5th anniversary of the two organizations. We want to share with you a summary and reflection on this year’s events and campaigns moving our mission forward and message delivered worldwide. The mission and promoting C.diff. Awareness has been shared this year alone with over 81,453 listeners during Season III on C. diff. Spores and More Global Broadcasting Network (www.cdiffradio.com),  5,000+ visitors during global events, 9,600+ residents and business owners throughout villages and communities by our dedicated volunteer patient advocates, over 1,000 clinicians received up-to-date data expanding their knowledge during workshops and local symposiums offered worldwide, 3,000+ incoming national hot-line calls, with thousands of e-mails seeking information.

After each event, workshop, meeting — we thank the individuals for the five years of opportunity to provide the life-saving data educating and advocating for C. difficile infection prevention, treatments, environmental safety and support worldwide.  The mission of the C Diff Foundation is the momentum of charity that has proven effective and grown over the past five years.  A single act of charity grows into more and greater charity worldwide.  The work each member of the C Diff Foundation with the hundreds of Volunteer Patient Advocates, promote the Foundation’s mission which never stops with a single act.  Instead, it builds, it grows, and it expands into an exponential impact of good in the world helping to save lives.  We thank you for your continued support and encourage you to continue your journey, proposing three verbs important to the C Diff Foundation and the C diff Survivors Alliance Network in general.

The first of these verbs is “to promote” C.diff. Awareness. It is the first step that opens doors in educating individuals, clinicians, communities in learning more about this life-threatening infection which causes a great amount of pain and suffering around the globe.  It is essential and it is the compass in reaching shared goals.

The second verb is “to heighten awareness” across the nation to continue proclaiming November Clostridium difficile infection awareness month. The Governors proclaimed November C. difficile (C.diff) infection awareness month in 2017 and we encourage them “to welcome” this proclamation in 2018 with more than a yearly executive order of greeting or inviting their residents to take notice.  We look forward to working with delegates, with your support, to make this proclamation statement nationwide and welcome the importance of the time, education, programs, and agenda in place addressing this life-threatening infection.  The C Diff Foundation advocates and supports the individuals and families suffering during and after being treated for a C. diff. infection.

Finally, the third verb that the C Diff Foundation and C diff Survivors Alliance Network propose is “to go.”  Here we are all challenged to do something with the gifts we have been given and what we are able to do.  With the unity of members with volunteers with the patients, families, and clinicians we can make a difference with enthusiasm and simplicity to get up and go.  We can do for others what we could not do for ourselves during our illnesses, during the isolation, during the losses, during the pain and suffering.  As members of the C Diff Foundation we know that our enthusiasm  for our mission is the desire to bring awareness and
promote C. difficile infection prevention, treatments, environmental safety and support worldwide.  We witness the change by delivering the data and information within villages,  through major cities and  small communities — it is only by taking this path that we gain satisfaction knowing that the news is delivered with enthusiasm “to promote, to heighten awareness and to go” with the members and volunteers in the C Diff Foundation and C diff Survivors Alliance Network.

We are truly grateful for your continued dedication, efforts and support and thank you again for making this year’s November anniversary such a special occasion through the growth and advances made worldwide.   Let’s carry the mission into the New Year, carving new paths to witness the decline in newly diagnosed cases of Clostridium difficile (C.diff., C. difficile) infections and saving lives worldwide.

“None of us can do this alone ~ All of us can do this together.”

 

 

Recurrent C. diff. Infection; Begins With An Antibiotic and Ends With a FMT

Name: Melissa cabral

Email: melissacabral918@yahoo.com

Your Story: I developed c diff colitis in July 2012 following clindamycin for a root canal. The first time I was in the hospital for 8 days. I had recurrent c diff after that until I finally had a fecal transplant. My husband was going to be my donor but he tested positive for c diff as well. My mother ended up being my donor and I’ve been c diff free ever since.

 

Recurrent C. diff. Infection Forces a Healthcare Professional Into Early Retirement

Name: Angie Martin

Your Story: I am a retired healthcare professional, I could not even begin to tell u what I have been thru the last 4 -1/2 yrs….from my FMT’s – to all going on now with my digestive system…IBS/ulcerative colitis, acid reflux and a few polyps that was benign..to having to be very careful with antibiotics. Allergic to quite a few..very slim margin for me for antibiotics..so I don’t get c diff…I dealt with it for almost 3 yrs. A neg result is good news for me…I have been having problems now for the last 6 weeks. But don’t let it get me down. On rocky rd now…I can test neg in stool but yet be positive for it. I have changed my diet..a lot of changes in the last 5 yrs. Please never feel guilty. God made each and everyone of us unique..enjoy life the best we can.

Kudos to this group and the C Diff Foundation   Cdifffoundation.org

College and A C. diff. Infection; A Note From a Student Beating the Odds

Name: Rebecca

C.diff.Survivors Name/s: Rebecca

Comment: I have beaten two rounds of c diff! While this was going on, I still managed to work on my college degree, make deans list, and help others. God put it on my heart to say this: when you put your mind to it, you can beat this!

Every day is a new opportunity and miracles happen every day!

Happy Mother’s Day and Good-Health Wishes To Women Around the Globe

Happy Mother’s Day to Women Everywhere!

This year In the United States, Mother’s Day is celebrated on May 14th.

In more than 90 countries Mother’s Day will be celebrated, including many countries where the U.S. based C Diff Foundation is located.

We take this opportunity to celebrate and remember mothers everywhere and the invaluable role that mothers play in families, communities, and business.

The C Diff Foundation is dedicated to educating and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety with support around the globe. There are many avenues connected to C. difficile infections which lead the C Diff Foundation Members and Volunteer Patient Advocates down adjacent roads raising awareness of antibiotic-resistance, antibiotic stewardship programs, Sepsis, and a multitude of general wellness topics around the world.

The C Diff Foundation offers programs enabling healthcare professionals, patients and their families the ability to receive assistance needed during and post-CDI, the ability to receive support care without having to travel during and after experiencing a C. difficile infection, and through the continued support of members and volunteer patient advocates the C Diff Foundation’s mission progresses and grows.  Life-saving information reaches villages to cities raising CDI Awareness driving down newly diagnosed CDI’s worldwide.

This week, we will celebrate the success stories of mothers, their mothers, and generations of women, now C.diff. Survivors,  living in communities around the world where the C Diff Foundation can be found.

We will also be remembering the thousands of families who have lost their mother to a C. diff. infection and C. diff. infection involvement.

Happy Mother’s Day and good-health wishes are sent to women everywhere!

ridinilazole Efficacy and Safety Compared With Vancomycin For C. difficile Infection Treatment: Phase 2 Randomized,Double-Blind,Active-Controlled,Non-Inferiority Study

Article Summary:

Background

Clostridium difficile infection is the most common health-care-associated infection in the USA. We assessed the safety and efficacy of ridinilazole versus vancomycin for treatment of C difficile infection.

Methods

We did a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Participants with signs and symptoms of C difficile infection and a positive diagnostic test result were recruited from 33 centres in the USA and Canada and randomly assigned (1:1) to receive oral ridinilazole (200 mg every 12 h) or oral vancomycin (125 mg every 6 h) for 10 days. The primary endpoint was achievement of a sustained clinical response, defined as clinical cure at the end of treatment and no recurrence within 30 days, which was used to establish non-inferiority (15% margin) of ridinilazole versus vancomycin. The primary efficacy analysis was done on a modified intention-to-treat population comprising all individuals with C difficile infection confirmed by the presence of free toxin in stool who were randomly assigned to receive one or more doses of the study drug. The study is registered with ClinicalTrials.gov, number NCT02092935.

Findings

Between June 26, 2014, and August 31, 2015, 100 patients were recruited; 50 were randomly assigned to receive ridinilazole and 50 to vancomycin. 16 patients did not complete the study, and 11 discontinued treatment early. The primary efficacy analysis included 69 patients (n=36 in the ridinilazole group; n=33 in the vancomycin group). 24 of 36 (66·7%) patients in the ridinilazole group versus 14 of 33 (42·4%) of those in the vancomycin group had a sustained clinical response (treatment difference 21·1%, 90% CI 3·1–39·1, p=0·0004), establishing the non-inferiority of ridinilazole and also showing statistical superiority at the 10% level. Ridinilazole was well tolerated, with an adverse event profile similar to that of vancomycin: 82% (41 of 50) of participants reported adverse events in the ridinilazole group and 80% (40 of 50) in the vancomycin group. There were no adverse events related to ridinilazole that led to discontinuation.

Interpretation

Ridinilazole is a targeted-spectrum antimicrobial that shows potential in treatment of initial C difficile infection and in providing sustained benefit through reduction in disease recurrence. Further clinical development is warranted.

Funding

Wellcome Trust and Summit Therapeutics.

 

To read the article in its entirety, please click on the following link:

http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30235-9/fulltext

 

Dr Richard J Vickers, PhD'Correspondence information about the author Dr Richard J Vickers

 

Glenn S Tillotson, PhD

,

Richard Nathan, MD

,

Sabine Hazan, MD

,

John Pullman, MD

,

Christopher Lucasti, DO

,

Kenneth Deck, MD

,

Prof Bruce Yacyshyn, MD

,

Benedict Maliakkal, MD

,

Yves Pesant, MD

,

Bina Tejura, MD

,

Prof David Roblin, FRCP

,

Prof Dale N Gerding, MD

,

Prof Mark H Wilcox, MD

for the

 

See appendix for full details of the CoDIFy study group
Published: 28 April 2017
Open Access Article has an altmetric score of 76

Open access funded by Wellcome Trust